SmallCaps
ASX:SNTPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals

SYNTARA ORD

$0.027
+$0.001 (+1.92%)
Day Range
$0.026 - $0.027
52 Week Range
$0.023 - $0.083
Volume
824.49K
Avg Volume (10D)
2.79M
Market Cap
$49.74M
Price Chart
Market Statistics
Open$0.027
Previous Close$0.026
Day High$0.027
Day Low$0.026
52 Week High$0.083
52 Week Low$0.023
Valuation
Market Cap49.74M
Shares Outstanding1.88B
Price to Book4.00
Trading Activity
Volume824.49K
Value Traded21.45K
Bid$0.026 × 2,292,973
Ask$0.027 × 2,333,266
Performance
1 Day0.00%
5 Day-3.70%
13 Week-18.75%
52 Week-64.86%
YTD-25.71%
Technical Indicators
RSI (14)39.99
50-Day SMA$0.030
200-Day SMA$0.031
Latest News
Syntara advances myelofibrosis trial with Phase 2 data and SNT-5505 FDA fast track designation
Biotechnology

Syntara advances myelofibrosis trial with Phase 2 data and SNT-5505 FDA fast track designation

Clinical-stage drug developer Syntara (ASX: SNT) has hit more milestones with its SNT-5505 blood cancer treatment candidate. The company informed shareholders that it has obtained further positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 in combination with ruxolitinib  (RUX) for the treatment of myelofibrosis. Myelofibrosis is a type of blood cancer […]

1 min read
Colin Hay
Colin Hay